During the corresponding time, Nutra Pharma Corp saw a revenue deteriorated by -59.23 % year on year, sequentially revenue grew by 26.49 %. While revenue at the Nutra Pharma Corp 's corporate clients
Nutra Pharma's Comment on Sales, Marketing and Customers
The company operates in the human over-the-counter pain relief and companion animal pain relief markets. Its product portfolio includes Nyloxin, an over-the-counter pain medication intended for marketing and distribution in Canada pending regulatory approval; Pet Pain-Away, a homeopathic pain reliever for chronic pain in companion animals such as dogs and cats, marketed globally through DEG Productions and available on Amazon.com, Chewy.com, and www.petpainaway.com; Luxury Feet, an over-the-counter pain reliever for women experiencing pain from high heels, sold on www.luxuryfeet.com and Amazon; and Equine Pain-Away, a topical solution for chronic pain in horses, distributed through various retailers and online at www.EquinePainAway.com and Amazon. The company has collaborated with hospitals for clinical studies and partners with distributors and marketing entities including Nature’s Clinic, Lumaxa Distributors, DEG Productions, as well as trainers and veterinarians in the equine industry. The active pharmaceutical ingredient in its products is Asian cobra venom, which is approved under the Homeopathic Pharmacopoeia of the United States (HPUS). Customers and markets identified in company filings include DEG Productions, Lumaxa Distributors, and Nature’s Clinic.
Nutra Pharma’s Comment on Sales, Marketing and Customers
The company operates in the human over-the-counter pain relief and companion animal pain relief markets. Its product portfolio includes Nyloxin, an over-the-counter pain medication intended for marketing and distribution in Canada pending regulatory approval; Pet Pain-Away, a homeopathic pain reliever for chronic pain in companion animals such as dogs and cats, marketed globally through DEG Productions and available on Amazon.com, Chewy.com, and www.petpainaway.com; Luxury Feet, an over-the-counter pain reliever for women experiencing pain from high heels, sold on www.luxuryfeet.com and Amazon; and Equine Pain-Away, a topical solution for chronic pain in horses, distributed through various retailers and online at www.EquinePainAway.com and Amazon. The company has collaborated with hospitals for clinical studies and partners with distributors and marketing entities including Nature’s Clinic, Lumaxa Distributors, DEG Productions, as well as trainers and veterinarians in the equine industry. The active pharmaceutical ingredient in its products is Asian cobra venom, which is approved under the Homeopathic Pharmacopoeia of the United States (HPUS). Customers and markets identified in company filings include DEG Productions, Lumaxa Distributors, and Nature’s Clinic.
Sources:
Nutra Pharma Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nutra Pharma Corp’s corporate clients.
For your research, we’ve provided 9 tables on Nutra Pharma Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
